Skip to main
OPCH

OPCH Stock Forecast & Price Target

OPCH Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 30%
Buy 60%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Option Care Health is facing headwinds in its autoimmune and chronic inflammatory patient census due to changes in insurance plan benefits. However, the company's exposure to these factors is expected to decrease in the future with Stelara and its biosimilars representing a small portion of its overall revenue. The company is also working to improve its efficiency and cost management through investment in advanced practitioner capabilities and optimization of procurement activities. Despite potential risks in the specialty pharmacy space, we believe that OPCH represents an excellent longer-term value with opportunities for revenue growth and margin improvement in the coming years.

Bears say

Option Care Health is facing headwinds in its top line performance, particularly due to unexpected challenges with the Stelara therapy and increased competition. This, coupled with a decline in revenue and cash generation, will make it difficult for the company to achieve its targets for adjusted EBITDA and adjusted EPS in 2026. Additionally, the company's previous exposure to single drug/single therapy risk (Stelara) has been de-risked, but there are still doubts about the feasibility of their projected 2H/26 ramp in adjusted EBITDA. This could lead to increased skepticism from investors and potential underperformance of the stock.

OPCH has been analyzed by 10 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 60% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Option Care Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Option Care Health (OPCH) Forecast

Analysts have given OPCH a Buy based on their latest research and market trends.

According to 10 analysts, OPCH has a Buy consensus rating as of May 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $79.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $79.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Option Care Health (OPCH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.